Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x80px
Document › Details

Intrexon Corporation. (10/24/18). "Press Release: Intrexon Announces the Formation of Bioinformatics Hub in Munich. Establishing itself as Intrexon Bioinformatics Germany GmbH (IBG)". Germantown, MD.

Region Region München (Munich)
  Country Germany
Organisations Organisation Intrexon Corporation (NYSE: XON)
  Group Intrexon (Group)
  Organisation 2 Intrexon Bioinformatics Germany GmbH (IBG)
  Group Intrexon (Group)
Products Product bioinformatics (biological software and databases)
  Product 2 genomic software tools
Person Person May, Klaus J. W. (Genomatix 200411)
     


Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the formation of Intrexon Bioinformatics Germany GmbH, a Munich-based bioinformatics company. Now a part of IBG, the Munich-based group of bioinformatics industry leaders have developed software tools focused on mapping genomic, transcriptomic, and epigenomic function in eukaryotic microbes and multicellular organisms employing diverse experimental inputs (microarray, ChipSeq, and Next-Gen Sequencing (NGS)). Their bioinformatics software solutions are designed to enable scientists to develop a robust model of biological "reality" from which to design both Discovery and Applied Research experiments.

"For the last 20 years, the German bioinformatics team has developed award-winning software tools and managed global services for mapping and analyzing complex eukaryotic genomes. Because Intrexon is a leader in the development of targeted, controllable, and multigenic gene networks for the reprogramming of cells and organisms, we are honored to have this highly experienced team expand and improve our library of genetic regulatory components focused on human therapeutics and animal science," said Thomas Reed, PhD, Founder and Chief Science Officer of Intrexon.

Klaus May, PhD, leader of the Munich based team, stated, "We are very proud of our team's rich scientific history, pioneering the analysis and understanding of eukaryotic gene regulation. Our bioinformatics team has published more than 160 peer reviewed scientific papers in journals like Cell, Nature, and Science and generated more than 6,000 citations, and we've supported over 30,000 global customers."

Dr. May added, "I am very excited about the fantastic opportunity of being a part of the Intrexon family because our scientific team can now directly contribute to the design of advanced therapeutic products and food animals with traits focused on biosustainable improvements in productivity and disease resistance. While we will continue to offer a subset of our online software tools to the larger scientific community, we are pleased to announce that our scientists will employ our proprietary database and tools to identify disease targets, suggest therapeutic interventions, and design the regulatory components (promoters, enhancers, and other inter- and intra-genomic regulatory elements) to augment Intrexon's existing technology platforms."


About Intrexon Corporation

Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet. Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.


Trademarks

Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.


Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.


For more information regarding Intrexon Corporation, contact:

Investor Contact:
Steven Harasym
Vice President, Investor Relations
Tel: +1 (214) 721-0607
investors@dna.com

Corporate Contact:
Marie Rossi, PhD
Vice President, Communications
Tel: +1 (301) 556-9850
publicrelations@dna.com

   
Record changed: 2018-10-24

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Intrexon (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px




» top